Novo Says New Obesity Pill Success Will Limit Sales Decline

Novo Nordisk A/S’s new Wegovy obesity pill fueled sales in the first quarter and the drugmaker said this year’s declines won’t be as bad as expected.

The worst drop for both profit and sales will likely be 12% this year, compared with an earlier forecast of 13%, the Danish company said Wednesday. The shares surged as much as 9.2% in Copenhagen, roughly halving their decline for the year.